Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

NCT04197713 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

13

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions

DRUG: Adavosertib
DRUG: Olaparib

Sponsor

National Cancer Institute (NCI)